Keyßer Gernot
Bereich Rheumatologie, Department für Innere Medizin, Klinik für Innere Medizin II, Universitätsklinikum Halle, Ernst-Grube-Str. 40, 06097, Halle (Saale), Deutschland.
Z Rheumatol. 2021 May;80(4):295-304. doi: 10.1007/s00393-021-00972-x. Epub 2021 Mar 11.
Glucocorticoids (GC) are still the recommended initial treatment for rheumatoid arthritis, although the treatment should be temporary and confined to the administration of low doses. The complex mechanism of action is accompanied by side effects that particularly occur in long-term treatment exceeding 5 mg prednisolone per day. In this dosage range they promote osteoporosis, diabetes and hyperglycemia as well as cardiovascular events and infections, thereby contributing to an excess mortality. The risks of GC treatment are dependent on patient-related parameters, such as age, comorbidity and additional medication. A negative influence of very low steroid doses on overall survival is possibly due to high cumulative steroid doses; however, the data in this respect are contradictory. Recently, a validated index was developed to monitor GC-related toxicity. In the future, this index should help to describe the advantages of steroid-sparing treatment strategies. In the future, more selectively acting substances could achieve an uncoupling of desired and adverse effects.
糖皮质激素(GC)仍然是类风湿性关节炎推荐的初始治疗药物,尽管该治疗应是临时性的且限于低剂量给药。其复杂的作用机制伴随着一些副作用,这些副作用尤其发生在长期治疗中,即每天泼尼松龙剂量超过5毫克时。在此剂量范围内,它们会引发骨质疏松、糖尿病和高血糖以及心血管事件和感染,从而导致额外的死亡率。GC治疗的风险取决于患者相关参数,如年龄、合并症和其他药物治疗情况。极低剂量的类固醇对总体生存率的负面影响可能归因于高累积类固醇剂量;然而,这方面的数据相互矛盾。最近,开发了一个经过验证的指数来监测与GC相关的毒性。未来,该指数应有助于描述类固醇节省治疗策略的优势。未来,更具选择性作用的物质可能实现期望效果与不良效果的解耦。